echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Interrupted for 5 months!

    Interrupted for 5 months!

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    A few days ago, Bluebird said that the European Union Pharmacovigilance Risk Assessment Committee (PRAC) has determined that Zynteglo's treatment benefits outweigh the risks and decided to re-approve the drug to enter the European blood disease treatment market


    The suspension of the Bluebird Zynteglo trial can be traced back to February this year, when Bluebird voluntarily stopped selling Zynteglo.


    Because Zynteglo and LentiGlobin use the same BB305 viral vector, Bluebird has suspended the drug's sales due to the same safety considerations


    Earlier last week, the European Medicines Agency (EMA) Safety Committee ruled that there was no evidence that the viral vector used by Zynteglo stimulated patients to produce AML cases


    Since Zynteglo received conditional approval for the treatment of transfusion-dependent β-thalassemia (TDT) in 2019, the safety review has experienced a series of setbacks


    After European regulators expressed the need to "tighten up" gene therapy, Bluebird delayed the launch of Zynteglo until 2020


    In the United States, Zynteglo has not yet received FDA approval, but the company said it may submit an application at any time


    In addition to safety issues, the price of the drug is also the focus of attention


    Reference source: After 5-month hiatus, bluebird bio's Zynteglo bounces back in Europe with all-clear from safety group

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.